前列腺癌免疫治疗新进展——sipuleucel-T  

Progress of immunotherapy for prostate cancer:sipuleucel-T

作　　者：白涛[1] 张杰[1] 

机构地区：[1]武汉大学人民医院泌尿外科,武汉430060

出　　处：《世界临床药物》2009年第11期646-649,共4页World Clinical Drug

摘　　要：治疗性抗前列腺癌疫苗sipuleucel-T(Provenge)给临床前列腺癌治疗带来新希望。其治疗的基本程序是分离患者的CD45+白细胞,于体外暴露于融合蛋白PA2024后,再将其经静脉回输给患者。临床接受sipuleucel-T治疗者可获得一定程度的免疫应答,但不少病例仍未能达到预期效果。未来的研究重点可能为sipuleucel-T与免疫调节因子相结合,以提高机体免疫应答。Sipuleucel-T(Provenge) is a new anti-prostate cancer immunotherapy product.The novel strategy includes extracting CD45+ leucocytes from patients,incubating them with recombinant antigen and re-infusing into patient s body to bolster their immune ability to recognize and kill tumor cells.Although the outcomes of clinical trials were not so satisfactory,such an individual,immunotherapeutic approache had demonstrated huge significance to clinical medicine.

关 键 词：前列腺肿瘤 疫苗 激素抵抗 激素依赖 

分 类 号：R737.25[医药卫生—肿瘤]